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Objective: This study evaluates the dose distribution of the three-dimensionally planned
conformal radiation therapy (CRT) compared to the previously used (5 years ago) arc
radiotherapy (ARCRT) of the brain cancer patients in Clinical Oncology and Nuclear Med-
icine Department e Mansoura University.
Patients and methods: Thirty-three unselected brain cancer patients were planned by both
the standard CRT and ARCRT techniques for radiotherapy of the brain. Doseevolume
histograms were carried out by the 3D treatment planning system. They were assessed for
the GTV, CTV, PTV and organs at risk. The prescribed total dose was 60 Gy in 30 fractions.
Results: Comparing different DVHs, it was found that, the GTV, CTV and PTV were
adequately covered in both (CRT & ARCRT) plans while it was demonstrated that ARCRT
produced superior distribution compared to CRT technique, with considerable sparing of
organ at risk.
Conclusion: The tangential beam ARCRT planning demonstrated a significantly better ho-
mogeneity index for the GTV, CTV, and PTV of the brain cancer patients with a significant
reduction in the mean doses of the both eyes, optic nerves, optic chiasm and brain stem.
Copyright © 2014, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Approximately 50% of patients diagnosed for cancer receive
radiotherapy as a part of their oncologic management. So,
balancing the potential for early and late toxicity against
tumor control is particularly important (Syam Kumar, Holla,
Sukumar, Padmanaban, & Vivekanandan, 2013).and Nuclear Medicine
m (T. Dawod), ro_elsayed
gyptian Society of Radiat
iety of Radiation Sciences
icense (http://creativecomRadiation therapy is a mainstay of the management of
most malignant and a significant number of benign primary
CNS tumors. Radiotherapy may be the main treatment if the
brain tumor can't be removedwith surgery. It's also often used
after surgery to treat any cancer cells that may have been left
behind, and can sometimes be used if the tumor has come
back after surgery. Radiotherapy may sometimes be given
along with chemotherapy tablets to some people with high-Department, Mansoura University Hospitals, Egypt. Tel.: þ20
@yahoo.com (R. Omar).
ion Sciences and Applications.
andApplications. Production and hosting by Elsevier B.V. This is an
mons.org/licenses/by-nc-nd/3.0/).
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type and size of brain tumor, but it is usually 2e6 weeks. Some
people will have different treatment plans and may have
treatment on only three days a week (Khan, 2007; Levitt,
Purdy, Perez, & Vijayakumar, 2006). There has been a gen-
eral change in treatment planning from 2D using a simulator
to 3D based on a CT scan and it has been shown that virtual
simulation of cancer patients may be more time effective
(Buchali et al., 2001). The technological development of ac-
celerators with multi-leaf collimators has also offered some
new possibilities for more time saving treatment techniques
compared to techniques with field matching between photon
and electron fields (Sonnik et al., 2007).
Rotation therapy is a special case of the isocentric tech-
nique in which the beam moves continuously about the pa-
tient, or the patient is rotated while the beam is held fixed.
Although this technique has been used for treating tumors of
the esophagus, bladder, prostate gland, cervix, and brain, the
technique offers little advantage over the isocentric technique
using multiple stationary beams. Rotation therapy is best
suited for small, deep-seated tumors. If the tumor is confined
within a region extending not more than halfway from the
center of the contour cross-section, rotation therapy may be a
proper choice. However, rotation therapy is not indicated if (a)
volume to be irradiated is too large, (b) the external surface
differs markedly from a cylinder, and (c) the tumor is too far
off center (Khan, 1994).
The goal of three-dimensional conformal radiation therapy
(3D-CRT) is to increase the likelihood of tumor control while
minimizing irradiation of normal surrounding tissues by
precise conforming the dose distribution to the target volume
shape (Marks et al., 2000; Mileusnic, 2005).
Doseevolume histograms (DVHs) are commonly used to
compare radiation treatment beams designed using tradi-
tional techniques with those planned using 3D tools. The
structures chosen for the DVHs comparison are typically
those that are incidentally irradiated using traditional
methods (Awad, Zayed, Abotouk, & Dawood, 2012; Donovan
et al., 2007).
This study evaluates the dose distribution of planned
conformal radiation therapy (CRT) compared to arc radio-
therapy (ARCRT) of the brain and through its effect on target
coverage and normal tissue sparing for cancer patients.2. Patients and method
CT datasets of 33 patients with brain cancer who received
radical radiotherapy treatment in our department were
randomly selected for this comparative planning study. All
patients underwent CT simulation; 3 mm slice thickness in
the supine position on the brain board. The instructions for
the PTV delineation were strictly followed in accordance with
the ICRU-62 guidelines. Gross tumor volume (GTV)-to clinical
target volume (CTV) margins of 10 mm were applied. Margins
of 5 mm were added to generate the planning target volume
(PTV) primarily in order to account for targetmotion (Cacicedo
et al., 2014; ICRU, 1999; Lee et al., 2007; Soyfer et al., 2012).
Organs at risk (OAR); right eye, left eye, right optic nerve,
left optic nerve, optic chiasm and brain stem weredelineated. 3D conformal plans and conventional ARC plans
were calculated with the integrated full area based com-
mercial planning system precise plan developed by ELEKTA.
Conventional arc modulation is optimized with variation of
gantry position with conventional jaw-positions and colli-
mator angle. Two plans were subsequently generated using
consistent planning parameters such as field arrangements,
optimization parameters and beam weights. First, a 3D plan
using 2e3 conformal beams (ELEKTA). Second, a conven-
tional arc therapy using 1e3 beams. The dose calculations
were performed using homogeneity corrections and full in-
tegrated area algorithm. Physicians selected the preferred
plan after comparing dose distributions by carefully assess-
ing the best DVHs with attention to V5, V10, V20, and V50 to
OAR and Mean dose, for target volumes the comparison
made between maximum dose, minimum dose, mean dose,
conformity index, homogeneity index, and uniformity index.
The parameters used for target volumes were V95, D2%, D5%,
D50%, D95%, and D98%. The most frequently selected energy of
photons was 6 MV. The number of the fields per planning
was 2e3 for the conformal 3D, 1e3 for conventional ARC
therapy.
Conformity index (CI), represents an attempt to measure
objectively how well the distribution of radiation follows the
shape of target, which is a ratio of the volume of tissue
receiving at least 95% of the prescribed dose divided by the
volume of the PTV (Equation (1)). A CI value closer to 1 is more
conformal (Foroudi et al., 2012).
CI ¼ V95%
VPTV
(1)
The homogeneity index (HI) was also calculated and is the
difference between the near-maximum and near-minimum
dose normalized to the median dose (Equation (2)) and mea-
sures the dose homogeneity across the PTV. An HI value
approaching zero indicates a more homogenous dose distri-
bution within the PTV (Foroudi et al., 2012; Wu, Mohan,
Morris, Lauve, & Schmidt Ullrich, 2003).
HI ¼ D2%  D98%
D50%
(2)
where D2% and D98% represent the doses to 2% and 98% of the
PTV, respectively. For example, D98 indicates that at least 98%
of the target volume receives this dose, and hence D2% and
D98% are considered to be the maximum and minimum doses,
respectively. Equation (2) shows that lower HI values indicate
a more homogenous target dose (Yoon et al., 2007).
UI ¼ D5
D95
(3)
where D5 and D95 are the minimum doses delivered to 5% and
95%, respectively of the PTV as previously described by Sheng
et al. (2007) and Wang, Zhang, and Dong (2005). The values of
the above parameters of 33 patients planned by ARC therapy
with CRT techniquewere comparedwith the help of their dose
volume histograms. The statistical approach was to extract
the two-tailed p-value via independent T testing, using two-
sample distributions assuming unequal variances, A p-value
of p < 0.05 was considered statistically significant.
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Using SPSS 16 statistical program, numerical data were sum-
marized using means and standard deviations or median and
ranges. Comparisons between ARCRT and CRT plans were
performed, nonparametric test equivalent to the paired test to
be used for small sample size. All p-values are two-sided. p
Values < 0.05 were considered significant.3. Results
The present work is a prospective study performed on 33 pa-
tients who met the inclusion criteria during the period of
study. After a lumpectomy radiotherapy for brainwas decided
for all included patients. Conformal radiation therapy (CRT)
and ARC radiotherapy (ARCRT) plans were done for each pa-
tient. On comparing the plan parameters of the brain, both
CRT and ARCRT planning techniques showed acceptable dose
distributions to the target volumes (GTV, CTV, and PTV) while
ARCRT showed an improvement of the PTV coverage and
sparing of all organs at risk except brain tissue.
Thirty-three patients were treated at Radiotherapy and
Nuclear Medicine Department, Mansoura University Hospital,
for brain,malignancies for curative and palliative intents from
January 2010 till April 2013. Eighteen patients were females
(54.54%), 15 were males (45.45%). The age of the whole group
ranged from 20 to 60 years, with median age of 40 years.
Themost frequent pathologywas glioblastoma in nineteen
patients (57.57%); Meningioma, in five patients (15.15%); as-
trocytoma, in four patients (12.12%), Others include PNET (1
patient); glioma (one patient); adrenocortical carcinoma (one
patient); pineal body (one patient); pituitary gland (one pa-
tient); and ependymoma (one patient).
Both two planning techniques produced acceptable dose
distributions to the target volumes. All the dose coverage pa-
rameters of GTV for the ARC therapy and CRT plans showed
similar and comparable values without significant differ-
ences. The isodose distributions obtained on an axial, coronal,
and sagittal slices at the isocenter plane of a representative
patient for ARC therapy and CRT shown in Fig. 1. The planFig. 1 e Comparison of dose distcomparison DVH curves for PTV and OARs of the same patient
ARC therapy and CRT shown in Fig. 2. The analyzed data of
thirty three patients with the mean doses to the GTV, CTV,
and PTV, and comparison of dose coverage with ARC therapy
and CRT treatment plans is shown in Table 1. The results
indicated that there was a statistically significant and
considerable difference in the dose coverage of GTV, CTV, and
PTV with ARC (p < 0.001) compared with CRT plans. Table 2
shows the minimum, maximum, and mean dose for both of
ARC and CRT.
3.1. Dose distribution in the target volume
The isodose distributions obtained on an axial slice at the
isocenter plan were compared for each patient regarding the
ARCRT and CRT. The comparison of plan DVH curves for GTV,
CTV, PTV and organs at risk (OARs) of a representative patient
for ARCRT and CRT are shown in Fig. 1. The analyzed data of
thirty three patients with the mean, maximum and median
doses to GTV, CTV, PTV and comparison of dose coveragewith
ARCRT and CRT treatment plans is shown in Table 1.
Themean dose to the GTV for patients treated with ARCRT
was 100.16% (SD ¼ 1.51) with a median 100% (range 99e101%),
The mean dose to the CTV for patients treated with ARCRT
was 100.05% (SD ¼ 0.51) with a median 100% (range 99e101%),
and Themeandose to the PTV for patients treatedwith ARCRT
was 99.60% (SD ¼ 0.70) with a median 100% (range 97e100%).
While Themean dose to the GTV for patients treatedwith CRT
was 100.28% (SD ¼ 0.58) with a median 100% (range 99e101%),
and The mean dose to the CTV for patients treated with CRT
was 100.30% (SD ¼ 0.66) with a median 100% (range 99e101%),
and The mean dose to the PTV for patients treated with CRT
was 97.90% (SD ¼ 3.23) with a median 98% (range 86.5e106%).
The results indicate that there was a statistically significant
and considerable difference in the dose coverage of GTV and
PTV with ARCRT (p < 0.001) compared to CRT plans.
The median value of HI for ARCRT was 0.05 with a range
(0.013e0.093) for GTV, was 0.07 with a range (0.045e0.093) for
CTV, and 0.07 with a range (0.037e0.251) for PTV, while it was
0.05 with a range (0.009e0.094) for GTV, was 0.07 with a range
(0.016e0.137) for CTV, and 0.08 with a range (0.036e0.3) for
PTV, for CRT plan.ribution for ARCRT and CRT.
Fig. 2 e Doseevolume histogram of target volumes and organs at risk for one representative patient undergoing ARCRT and
CRT.
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1 with a range (0.985e1) for GTV, 1 with a range (0.95e1) for
CTV, and 0.99 with a range (0.83e1) for PTVwhile it was 1 with
a range (0.953e1) for GTV, 1 with a range (0.933e1) for CTV,
and 0.96 with a range (0.820e1) for PTV for 3D-CRT. The
average lower values of HI and higher values of CI for ARCRT
plans were compared to the CRT with statistical difference
that confirm the advantage of ARCRT plans over CRT plans.Table 1 e Comparison of the average dose parameters of 33 pa
planning techniques.
GTV parameter ARCRT
Mean SD Median Range
Maximum dose (%) 102.72 1.44 103.00 100e106
Mean dose (%) 100.16 0.447 100.00 99e101
HI 0.05 0.02 0.05 0.013e0.093
CI 1.00 0.00 1.00 0.985e1
UI 1.04 0.02 1.04 1.010e1.070
D2% 102.23 1.21 102.33 100e104.67
D98% 97.64 1.32 97.69 94.47e99.33
CTV parameter
Maximum dose (%) 103.75 1.29 104.00 100e106
Mean dose (%) 100.05 0.510 100.00 99e101
HI 0.06 0.02 0.07 0.045e0.093
CI 0.99 0.02 1.00 0.95e1
UI 1.06 0.01 1.06 1.034e1.077
D2% 102.92 1.05 103.23 100e104.60
D98% 96.40 0.97 96.67 94.47e98
PTV parameter
Maximum dose (%) 103.55 1.52 104.00 100e106
Mean dose (%) 99.60 0.704 100.00 97e100
HI 0.08 0.04 0.07 0.037e0.251
CI 0.98 0.04 0.99 0.83e1
UI 1.07 0.03 1.07 1.032e1.202
D2% 102.72 1.32 103.12 100e105.33
D98% 94.75 3.23 95.63 78e97.333.2. Dose distribution in organs at risk (OARs)
The dose coverage of organs at risk (OARs) with ARCRT and
CRT plans is shown in Table 2. Data represented were the
mean values for each organ with their standard deviation. For
brain cancer patients, Comparison of ARCRT and CRT plan-
ning shows large gain in healthy tissue sparing in favor of
ARCRT planning. There was statistical difference in the meantients for the PTV between ARCRT and CRT radiotherapy
CRT p Value
Mean SD Median Range
103.53 1.61 104.00 100e107 0.003
100.28 0.58 100.00 99e101 p < 0.001
0.05 0.02 0.05 0 0.009e0.094 p < 0.001
1.00 0.01 1.00 0.953e1 p < 0.001
1.05 0.02 1.04 1.013e1.085 0.002
102.62 1.28 102.80 100e105 0.001
97.31 1.42 97.40 94.8e100 0.001
105.35 2.16 105.00 101e110 0.005
100.30 0.66 100.00 99e101 0.001
0.07 0.02 0.07 0.016e0.137 0.049
0.99 0.02 1.00 0.933e1 p < 0.001
1.06 0.03 1.06 1.013e1.085 0.002
103.93 1.74 103.84 100.27e107.14 0.003
96.48 1.53 96.80 93.33e99 p < 0.001
104.94 2.40 105.00 100e111 0.004
99.70 0.85 100.00 97e101 p < 0.001
0.09 0.05 0.08 0.036e0.3 0.037
0.96 0.05 0.96 0.820e1 0.007
1.07 0.03 1.07 1.013e1.185 0.002
103.60 1.94 103.67 100e107.33 0.003
94.50 4.18 95.33 74.33e98.67 0.001
Table 2 e Comparison of the average dose distribution in the organs at risk (OARs) for 33 patients between ARCRT and CRT
planning techniques.
Organ at risk Technique N Mean Median Std. deviation Std. error mean p Value
Right eye ARCRT 33 2.82 2.00 2.57 0.45 p < 0.001 0.038
CRT 3.18 2.00 4.37 0.76 p < 0.001
Left eye ARCRT 2.09 2.00 1.61 0.28 p < 0.001 0.107
CRT 2.94 2.00 4.39 0.76 p < 0.001
Right optic nerve ARCRT 5.18 3.00 7.23 1.26 p < 0.001 0.077
CRT 6.61 3.00 13.49 2.35 0.01
Left optic nerve ARCRT 4.39 3.00 6.24 1.09 p < 0.001 0.084
CRT 5.73 3.00 7.90 1.38 p < 0.001
Optic chiasm ARCRT 7.65 4.00 16.16 2.90 0.01 0.074
CRT 9.67 3.00 16.86 3.08 p < 0.001
Brain stem ARCRT 7.00 3.00 18.12 3.49 0.06 0.105
CRT 9.78 2.00 19.36 3.73 0.01
Brain ARCRT 6.56 0.00 15.49 3.87 0.11 0.085
CRT 5.00 0.00 11.62 2.90 0.11
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showed better sparing in 3D planning. The mean right eye
dose reduced by an average of 11.32% in ARCRT plans
compared to CRT plans. There was insignificant p value
(p ¼ 0.038), dose reduction in left eye with ARCRT plans by
average of 28.91% with (p ¼ 0.107). The mean right optic nerve
dose was reduced by an average of 21.63% in ARCRT plans
compared to CRT plans with (p ¼ 0.077), while for left optic
nerve the dose reduced by 13.96% with (p ¼ 0.084). For optic
chiasm the mean dose was reduced by an average of 20.88%
with (p ¼ 0.074). The data reduced in brain stem for ARCRT by
28.42% than CRT with (p ¼ 0.105). Finally the mean dose for
brain tissue was reduced by an average of 23.785% in CRT
compared to ARCRT with (p ¼ 0.085). In all OARs the per-
centage of volumes receiving more than their tolerance doses
were reduced significantly with ARCRT plans compared with
both CRT plans.4. Discussion
In an ideal world, radiation treatment beams would fully
encompass the target tissue and exclude all normal tissues. In
practice, however, this is impossible due to the intimate
relationship between tumors and surrounding normal struc-
tures. Radiation treatment planning, therefore, is based on a
compromise between tumor and normal tissue consider-
ations (Marks et al., 2000).
ARC radiotherapy treatment planning is limited in its
ability to represent the prescribed dose delivered to a specific
target volume and to quantify the extent of irradiated normal
tissue to estimate normal tissue toxicity. Analysis of the dose
to normal tissues often performed using the DVHs that can be
generated using three-dimensional treatment planning,
providing estimates of the dose to target tissues and normal
structures. A DVH is a plot of dose of radiation on the x-axis
and percent volume of the structure of interest on the y-axis.
The shape and area under the DVH curve are used to ensure
that the target volume is adequately covered with a homog-
enous dose and that dose to critical structures is within
acceptable limits. A 3D planning system can calculate the
dose in each pixel of the organ outlined and sum these toproduce a DVH. 3D treatment planning is, therefore, a
powerful tool that can be used to compare treatment tech-
niques for adequacy of target coverage and complication risk
(Thomsen et al., 2008).
One of the most important benefits of a DVH is that pro-
vides an accurate assessment of homogeneity in the PTV. The
presence of defects in a dose distributionwill negatively affect
tumor control, and an accurate evaluation of homogeneity in
the PTV is therefore essential to the efficacy of the treatment
plan (Yoon et al., 2007). In the current study, we used both
homogeneity index and conformity index to evaluate target
coverage and dose homogeneity. Conformity index used to
evaluate the clinical evidence of better treatments. Improved
conformity may help to deliver higher doses to the PTV
without delivering more doses to the surrounding normal
tissue (Murthy et al., 2010). Both indices where statistically
better using CRT. This was demonstrated by the isodose dis-
tributions and DVH curves. A number of studies have
demonstrated a dosimetric benefit of different beam
arrangement techniques in the brain tumors (Zach et al.,
2009).
In this study, the comparison between ARCRT and CRT
techniques for the treatment of brain tumor types in thirty
three patients showed no significant difference in dose
coverage and distribution, while ARCRT planning provide
better OAR sparing except in brain tissue. This not similar to
what was showed previously by (Breen, Kehagioglou, Usher,&
Plowman, 2007) in a comparative study between ARC treat-
ment and CRT They found that all techniques were able to
provide acceptable coverage of the target volume. However,
ARC reduced the maximum dose to the target and dominant
OAR doses to less than 70% of themean target dose. Regarding
the homogeneity, it was found that there was no statistical
difference between ARCRT and CRT techniques. This was not
similar to what has been reported by (Oh, Antes, Darby, Song,
& Starkschall, 1999).5. Conclusion
The ARCRT planning demonstrated an improvement of GTV,
CTV and PTV coverage and significantly better homogeneity
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significant reduction in the mean doses of all organ at risk
except brain tissue. It should be noted that whereas the
maximum dose for the 360-degree rotation occurs at the iso-
center, for the partial arcs it is displaced toward the irradiated
sector. This illustrates an important principle that in arc
therapy orwhen oblique fields are directed& rough one side of
a patient, they should be aimed a suitable distance beyond the
tumor area. This is sometimes referred to as past pointing the
extent of past pointing required to bring themaximumdose to
the tumor site depends on the arc angle and should be
determined for an individual case by actual isodose planning.
The arc therapy in our research gives good results in tumors,
which found in peripheral region away from the critical or-
gans in the brain, with volumes of PTV 6  6  5 cm3.r e f e r e n c e s
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